Fitchburg, Wis. - Alex Vodenlich believes his life-science company, GenTel BioSciences, has taken a major step with the acquisition of a protein chip platform from GlaxoSmithKline, but just how major could depend on the degree to which the technology improves the quality of data GenTel delivers to customers.

G......

Full article >>> tional data.

Vodenlich said it would have taken GenTel a long time to duplicate the protein chip platform it purchased from GlaxoSmithKline. The platform integrates instruments, web-based software applications, and statistical tools that will enable GenTel to design and screen protein arrays, and analyze multiplex protein micro arrays. He said GenTel's customer base, including large pha......

Full article >>> /b>

In conjunction with the acquisition, GenTel has added to its staff Dr. Anna Astriab-Fisher, who will serve as vice president of assay development, and Bryan Reep, who brings expertise in the production of arrays. Assays are procedures in which the properties of an object are measured; arrays are genetic tools used to detect variations in DNA and susceptibility to disease, and measure ......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 03/13/07


Related biology technology :

1. New angel capital centered on GenTel agreement with big pharma
2. GenTel licenses next generation cancer research
3. GenTel to distribute cancer research tool
4. GenTel gets federal grant to develop allergy test
5. Madisons GenTel partners with Taiwan firm
6. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
7. GenTel BioSurfaces launches new assay platform
8. GenTel will sell Dutch firms biomolecule labeling technology
9. Bone Care, GenTel, MyWeather
10. GenTel receives $250,000 state loan
11. GenTel claims $900,000 in federal grants this year for biochip research